| 21 Oct 2025 |
Change of Director’s Interest – Tan Kia King (21 Oct 2025) |
| 16 Oct 2025 |
Media Release: Hyphens Pharma and medac Extend Metoject® Agreement to Thailand and Cambodia |
| 20 Aug 2025 |
Announcement: Result Briefing 1H FY2025 |
| 18 Aug 2025 |
Share Buy Back – Daily Share Buy-Back Notice (Market Acquisition) |
| 13 Aug 2025 |
Financial Statements and Related Announcement: Half Yearly Results (2025) |
| 17 Jul 2025 |
Media Release: Hyphens Pharma Introduces Novel Acne Treatment, Winlevi®, to Singapore and Malaysia |
| 17 Jun 2025 |
Change of Director’s Interest – Tan Kia King (17 Jun 2025) |
| 27 May 2025 |
Minutes of Annual General Meeting held on 28 April 2025 |
| 14 May 2025 |
Change of Director’s Interest – Tan Kia King (14 May 2025) |
| 09 May 2025 |
Asset Acquisitions and Disposals: Completion Of Proposed Acquisition Of Tranche 2 Sale Shares Of 17% In Ardence Pharma Sdn Bhd |
| 28 Apr 2025 |
Results of Annual General Meeting held on 28 April 2025 |
| 22 Apr 2025 |
Response to Substantial and Relevant Questions Received from Shareholders on Annual Report 2024 [Pre-AGM] |
| 21 Apr 2025 |
Change of Director’s Interest – Tan Kia King (21 Apr 2025) |
| 11 Apr 2025 |
Cash Dividend / Distribution: Mandatory (FY2024) |
| 11 Apr 2025 |
Notice of Annual General Meeting (FY2024) |
| 19 Mar 2025 |
Change of Director’s Interest – Tan Kia King (19 Mar 2025) |
| 11 Mar 2025 |
Media Release: Hyphens Pharma Obtains Exclusive Rights to Commercialise Metoject® |
| 27 Feb 2025 |
Change of Director’s Interest – Tan Kia King (27 Feb 2025) |
| 27 Feb 2025 |
Announcement: Result Briefing FY2024 |
| 25 Feb 2025 |
Financial Statements and Related Announcement: Full Yearly Results (2024) |
| 12 Nov 2024 |
Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2024 |
| 19 Sep 2024 |
Media Release: Hyphens Pharma Launches Ceradan® Advanced Hand Balm, Specially Designed for Hand Eczema |
| 28 Aug 2024 |
Media Release: Hyphens Pharma Wins Gold Award for Best Managed Board at Singapore Corporate Awards 2024 |
| 16 Aug 2024 |
Announcement: Results Briefing 1H 2024 |
| 14 Aug 2024 |
Financial Statements and Related Announcement: Half Yearly Results |
| 06 Jun 2024 |
Announcement: Resignation of Mr. Timothy Chen, CEO of DocMed Technology and Pan-Malayan Pharmaceuticals |
| 05 Jun 2024 |
Media Release: Hyphens Pharma licenses Amenalief® from Maruho for ASEAN |
| 24 May 2024 |
Announcement: Minutes of Annual General Meeting Held on 25 April 2024 |
| 14 May 2024 |
Announcement: Business Update for the First Quarter Ended 31 March 2024 |
| 13 May 2024 |
Share Buy Back – Daily Share Buy-Back Notice (Corrigendum to Notice dated 2 April 2024) |
| 25 Apr 2024 |
Results of Annual General Meeting held on 25 April 2024 |
| 23 Apr 2024 |
Change of Director’s Interest – Chan Kiat (23 April 2024) |
| 19 Apr 2024 |
Pre-AGM (FY2023): Address of Shareholders’ Queries & Proxy Form |
| 09 Apr 2024 |
Cash Dividend / Distribution: Mandatory (FY2023) |
| 09 Apr 2024 |
Notice of Annual General Meeting (FY2023) |
| 02 Apr 2024 |
Share Buy Back – Daily Share Buy-Back Notice (2 April 2024) |
| 02 Apr 2024 |
Change of Director’s Interest – Dr Tan Kia King (2 April 2024) |
| 25 Mar 2024 |
Change of Director’s Interest – Chan Kiat (25 March 2024) |
| 22 Mar 2024 |
Change of Director’s Interest – Dr Tan Kia King (22 March 2024) |
| 12 Mar 2024 |
Media Release: Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics |
| 06 Mar 2024 |
FY2023 Full-Year Financial Results Briefing |
| 29 Feb 2024 |
Media Release: Hyphens Pharma’s Ceradan range of products to enter major Middle East markets |
| 27 Feb 2024 |
Financial Statements and Related Announcement: Full Yearly Results |
| 06 Feb 2024 |
Media Release: Hyphens Pharma partners 7-Eleven to offer Ocean Health® supplements at selected convenience stores in Singapore |
| 08 Dec 2023 |
Employee Stock Option/Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan |
| 09 Nov 2023 |
Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2023 |
| 08 Nov 2023 |
Asset Acquisitions and Disposals: Completion Of Proposed Acquisition Of Tranche 1 Sale Shares Of 23% In Ardence Pharma Sdn Bhd |
| 19 Oct 2023 |
Announcement : Analyst Briefing – Acquisition of Ardence Malaysia |
| 17 Oct 2023 |
Asset Acquisitions and Disposals: Proposed Acquisition Of 58% Of The Share Capital In Ardence Pharma Sdn Bhd Over 3 Tranches |
| 30 Aug 2023 |
Media Release: Nabota® successfully registered in Malaysia |
| 17 Aug 2023 |
Announcement: Results Briefing 1H 2023 |
| 11 Aug 2023 |
Financial Statements and Related Announcement: Half Yearly Results |
| 11 Aug 2023 |
Cash Dividend / Distribution: Mandatory |
| 19 Jul 2023 |
Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd |
| 19 Jul 2023 |
Change of Director’s Interest – Mr Lim See Wah |
| 19 Jul 2023 |
Change of Director’s Interest – Dr Tan Kia King |
| 19 Jul 2023 |
Cessation of Substantial Shareholder’s Interest – Mr Tan Chwee Choon |
| 05 Jun 2023 |
(Board Approval) Hyphens Pharma International – Appointment of CFO |
| 24 May 2023 |
Minutes of Annual General Meeting and Extraordinary General Meeting held on 26 April 2023 |
| 17 May 2023 |
Announcement: Hyphens Pharma to develop and commercialise Byfavo procedural sedation drug in Singapore |
| 11 May 2023 |
Announcement: Business Update and Results Briefing for the First Quarter Ended 31 March 2023 |
| 28 Apr 2023 |
Employee Stock Option / Share Scheme: Allotment and Issuance of 422,000 New Ordinary Shares Under the Hyphens Performance Share Plan |
| 26 Apr 2023 |
Results of Extraordinary General Meeting held on 26 April 2023 |
| 26 Apr 2023 |
Results of Annual General Meeting held on 26 April 2023 |
| 21 Apr 2023 |
Response to Queries from SIAS on Annual Report 2022 |
| 21 Apr 2023 |
Response to Substantial and Relevant Questions Received from Shareholders before Annual General Meeting |
| 10 Apr 2023 |
Announcement of Cessation: Cessation of an Executive Director |
| 10 Apr 2023 |
Cash Dividend / Distribution: Mandatory (FY2022) |
| 10 Apr 2023 |
Notice of Extraordinary General Meeting |
| 10 Apr 2023 |
Notice of Annual General Meeting (FY2022) |
| 10 Apr 2023 |
Annual Reports and Related Documents |
| 06 Mar 2023 |
Announcement: Results Briefing FY2022 |
| 28 Feb 2023 |
Financial Statements and Related Announcement: Full Yearly Results |
| 10 Feb 2023 |
Media Release: Nabota® Successfully Registered in Singapore |
| 21 Dec 2022 |
Media Release: Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals |
| 05 Dec 2022 |
Media Release: Hyphens Pharma’s Meradan® Cream Launches in Indonesia |
| 09 Nov 2022 |
Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2022 |
| 15 Sep 2022 |
Announcement: Hyphens Pharma’s TDF Blu Voile Sunscreen |
| 17 Aug 2022 |
Announcement: Results Briefing 1H2022 |
| 11 Aug 2022 |
Financial Statements and Related Announcement: Half Yearly Results |
| 06 Jun 2022 |
Announcement: Completion of Investment in DocMed Technology |
| 31 May 2022 |
Sustainability Report 2021 |
| 27 May 2022 |
Corporate Presentation – DocMed |
| 27 May 2022 |
Hyphens Attracts S$6 million Investment in DocMed Technology to Grow Digital Healthtech |
| 12 May 2022 |
Announcement: Quarterly Business Update for the First Quarter Ended 31 March 2022 |
| 06 May 2022 |
Announcement of Cessation: Resignation of Chief Financial Officer |
| 27 Apr 2022 |
Results and Minutes of Annual General Meeting held on 27 April 2022 |
| 21 Apr 2022 |
Response to Substantial and Relevant Questions Received from Shareholders before Annual General Meeting |
| 12 Apr 2022 |
Cash Dividend / Distribution: Mandatory |
| 12 Apr 2022 |
Notice of Annual General Meeting |
| 12 Apr 2022 |
Annual Reports and Related Documents |
| 02 Mar 2022 |
General Announcement: Results Briefing FY2021 |
| 23 Feb 2022 |
Financial Statements and Related Announcement: Full Yearly Results |
| 26 Jan 2022 |
Change in Corporate Information: Change of Address of Share Registrar |
| 13 Jan 2022 |
General Announcement: Corporate Presentation |
| 10 Jan 2022 |
Hyphens Pharma Officially Launches WellAway, Singapore’s First HSA-Registered e-Pharmacy |
| 14 Dec 2021 |
Hyphens Pharma Has Inked Exclusive Licensing Deal of Ustekinumab Biosimilar |
| 09 Dec 2021 |
Asset Acquisitions and Disposals: Striking-Off of Indirect Wholly-Owned Subsidiary, DAC Pharmalab Pte Ltd |
| 03 Dec 2021 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 03 Dec 2021 |
Change of Director’s Interest – Dr Tan Kia King |
| 03 Dec 2021 |
Change of Director’s Interest – Mr Lim See Wah |
| 03 Dec 2021 |
Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd |
| 03 Dec 2021 |
Asset Acquisitions and Disposals: Completion of the Proposed Acquisition of 100% of the Issued Share Capital in Novem Group |
| 19 Nov 2021 |
General Announcement: Receipt of Approval In-Principle from SGX-ST for the Listing and Quotation for New Ordinary Shares |
| 16 Nov 2021 |
General Announcement: Acquisition of Novem & 3Q Business Update |
| 12 Nov 2021 |
General Announcement: Quarterly Business Update for the Third Quarter and Nine Months Ended 30 September 2021 |
| 09 Nov 2021 |
Request for Lifting of Trading Halt |
| 09 Nov 2021 |
Asset Acquisitions and Disposals: Entry into a Sale and Purchase Agreement Relating to the Proposed Acquisition |
| 08 Nov 2021 |
Request for Trading Halt |
| 10 Sep 2021 |
Change of Director’s Interest – Mr Lim See Wah |
| 10 Sep 2021 |
Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd |
| 18 Aug 2021 |
General Announcement: Results Briefing 1H2021 |
| 11 Aug 2021 |
Financial Statements and Related Announcement: Half Yearly Results |
| 17 May 2021 |
Sustainability Report 2020 |
| 12 May 2021 |
Change in Continuing Sponsor |
| 12 May 2021 |
Quarterly Business Update: 1Q2021 |
| 28 Apr 2021 |
Results and Minutes of Annual General Meeting held on 28 April 2021 |
| 13 Apr 2021 |
Notice of Annual General Meeting |
| 12 Apr 2021 |
Cash Dividend / Distribution: Mandatory |
| 12 Apr 2021 |
Annual Reports and Related Documents |
| 19 Mar 2021 |
Employee Stock Option / Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan |
| 05 Mar 2021 |
Change of Director’s Interest – Dr Tan Kia King |
| 05 Mar 2021 |
Change of Director’s Interest – Mr Lim See Wah |
| 05 Mar 2021 |
Change of Substantial Shareholder’s Interest – Inomed Holding Pte Ltd |
| 03 Mar 2021 |
General Announcement: Results Briefing FY2020 |
| 25 Feb 2021 |
Financial Statements and Related Announcement: Full Yearly Results |
| 18 Jan 2021 |
Hyphens Pharma Appoints Exclusive Distributor in South Korea for TDF Fairence® T-Complex |
| 07 Jan 2021 |
Hyphens Pharma Awarded e-Pharmacy Licence for WellAway Pharmacy |
| 16 Nov 2020 |
General Announcement: Results Briefing 3Q2020 |
| 12 Nov 2020 |
Hyphens Pharma Broadens Ceradan Brand’s Outreach to Mainland China |
| 11 Nov 2020 |
Financial Statements and Related Announcement: Third Quarter Results |
| 05 Nov 2020 |
General Announcement: Change in Composition of the Board of Directors and Board Committees |
| 05 Nov 2020 |
Announcement of Appointment: Appointment of an Independent Non-Executive Director |
| 03 Nov 2020 |
Hyphens Pharma Expands Ocean Health Distribution to Sri Lanka |
| 03 Sep 2020 |
Corporate Presentation |
| 18 Aug 2020 |
Intangible Asset Portfolio Review |
| 18 Aug 2020 |
General Announcement: Results Briefing 2Q2020 |
| 17 Aug 2020 |
Hyphens Pharma Inks Exclusive Partnership with SUTL to Distribute Ocean Health Products |
| 13 Aug 2020 |
Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results |
| 03 Aug 2020 |
Corporate Presentation at ASEAN Regional Healthcare Conference by DBS |
| 03 Aug 2020 |
Hyphens Pharma Expands Proprietary Brands Portfolio with Hair Loss Products |
| 24 Jul 2020 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 22 Jul 2020 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 15 Jul 2020 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 13 Jul 2020 |
Hyphens Pharma Receives UK Patent for Ceradan Advanced |
| 24 Jun 2020 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 12 Jun 2020 |
Results and Minutes of Annual General Meeting held on 12 June 2020 |
| 08 Jun 2020 |
Response to Queries from SIAS on Annual Report 2019 |
| 02 Jun 2020 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 01 Jun 2020 |
Change of Director’s Interest – Mr Tan Chwee Choon |
| 26 May 2020 |
Sustainability Report 2019 |
| 21 May 2020 |
Notice of Annual General Meeting |
| 14 May 2020 |
General Announcement: Results Briefing 1Q2020 |
| 11 May 2020 |
Cash Dividend / Distribution: Mandatory |
| 11 May 2020 |
General Announcement: Update on FY2019 Proposed Final Dividend of S$0.01 per Share |
| 11 May 2020 |
Financial Statements and Related Announcement: First Quarter Results |
| 28 Apr 2020 |
Response to Query Regarding Trading Activity |
| 27 Apr 2020 |
General Announcement – Voluntary Continuation of Quarterly Reporting and Deferment of Half-Yearly Reporting |
| 17 Apr 2020 |
General Announcement: Change in Composition of the Board of Directors and Board Committees |
| 17 Apr 2020 |
Announcement of Cessation: Resignation of an Independent Director |
| 09 Apr 2020 |
General Announcement: Business Continuity During Covid-19 Pandemic |
| 08 Apr 2020 |
Waiver: Extension of Time to Hold Annual General Meeting for Financial Year Ended 31 December 2019 |
| 08 Apr 2020 |
Annual Reports and Related Documents |
| 03 Mar 2020 |
General Announcement: Hyphens Results Briefing FY2019 |
| 26 Feb 2020 |
Financial Statements and Related Announcement: Full Yearly Results |
| 06 Feb 2020 |
General Announcement: TDF Fairence T-Complex has efficacy tests affirmed in Journal of Cosmetic Dermatology |
| 17 Dec 2019 |
General Announcement: Hyphens Pharma inks Research Collaboration Agreement with the Institute of Chemical and Engineering Sciences |
| 19 Nov 2019 |
General Announcement: Hyphens Results Briefing 3Q2019 |
| 14 Nov 2019 |
Financial Statements and Related Announcement: Third Quarter Results |
| 05 Nov 2019 |
Announcement of Cessation: Resignation of General Manager |
| 30 Aug 2019 |
Announcement of Appointment: Appointment of Chief Operating Officer |
| 19 Aug 2019 |
General Announcement: Hyphens Results Briefing 2Q2019 |
| 13 Aug 2019 |
Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results |
| 29 Jul 2019 |
Announcement of Appointment: Appointment of an Independent Non-Executive Director |
| 22 Jul 2019 |
General Announcement: Ocean Health revamped, unveils new and refreshed look |
| 10 Jul 2019 |
General Announcement: Hyphens Pharma launches New Ceradan Advanced |
| 17 Jun 2019 |
General Announcement: Hyphens Pharma first to introduce bioabsorbable metallic implants to Vietnam |
| 30 May 2019 |
General Announcement: Hyphens Pharma Signs Exclusive Distribution Agreement with Lundbeck for Vietnam |
| 17 May 2019 |
General Announcement: Corporate Presentations – Hyphens Results Briefing 1Q2019 |
| 17 May 2019 |
General Announcement: Corporate Presentations – Hyphens Presentation Deck |
| 17 May 2019 |
General Announcement: Corporate Presentations |
| 15 May 2019 |
Employee Stock Option / Share Scheme: Grant of Share Awards Pursuant to the Hyphens Share Plan |
| 13 May 2019 |
Financial Statements and Related Announcement: First Quarter Results |
| 26 Apr 2019 |
Annual General Meeting: Results and Presentation Slides |
| 18 Apr 2019 |
Asset Acquisitions and Disposals: Striking-Off Of Indirect Wholly-Owned Subsidiary – Ocean Healthcare (M) Sdn. Bhd. |
| 10 Apr 2019 |
Notice of Annual General Meeting |
| 10 Apr 2019 |
Annual Reports and Related Documents |
| 10 Apr 2019 |
Cash Dividend/Distribution: Mandatory |
| 21 Mar 2019 |
General Announcement: Hyphens Pharma Officially Opens Corporate Headquarters and Integrated Facility |
| 06 Mar 2019 |
General Announcement: Hyphens Results Briefing 4Q2018 / FY2018 |
| 28 Feb 2019 |
Financial Statements and Related Announcement: Full Yearly Results |
| 18 Feb 2019 |
General Announcement: Hyphens Pharma appoints Industry Veteran to head Dermatology Business Unit |
| 05 Dec 2018 |
General Announcement: Entry into Memorandum of Understanding with Doctor Anywhere |
| 13 Nov 2018 |
Financial Statements and Related Announcement: Third Quarter Results |
| 29 Sep 2018 |
Change in Corporate Information: Change of Registered Office |
| 29 Aug 2018 |
General Announcement: Corporate Presentation at INVEST Fair 2018 |
| 10 Aug 2018 |
Financial Statements and Related Announcement: Second Quarter and/or Half Yearly Results |
| 23 May 2018 |
General Announcement: Tenancy Agreement with RBC Investor Services Trust Singapore Limited |
| 18 May 2018 |
General Announcement: Balloting Result under Public Offer of Related Persons |
| 18 May 2018 |
Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Executive Chairman and CEO – Mr Lim See Wah |
| 18 May 2018 |
Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Executive Director – Mr Tan Chwee Choon |
| 18 May 2018 |
Disclosure of Interest/Changes in Interest of Director/Chief Executive Officer: Disclosure of interest by Non-Executive Director – Dr Tan Kia King |
| 18 May 2018 |
Disclosure of Interest/Changes in Interest of Substantial Shareholder(s)/Unitholder(s): Disclosure of interest by substantial shareholder – Inomed Holding Pte Ltd |
| 18 May 2018 |
General Announcement: Hyphens Pharma International Makes Strong Listing Debut on the Catalist Board of the SGX-ST |
| 17 May 2018 |
Equity – Listing Confirmation: Admission of 300,000,000 ordinary shares to the Official List of SGX-Catalist |
| 17 May 2018 |
General Announcement: Balloting Results |
